Premium
Modulated T‐complex protein 1 ζ and peptidyl‐prolyl cis‐trans isomerase B are two novel indicators for evaluating lymph node metastasis in colorectal cancer: Evidence from proteomics and bioinformatics
Author(s) -
Yue Fei,
Wang LiShun,
Xia Li,
Wang XiaoLing,
Feng Bo,
Lu AiGuo,
Chen GuoQiang,
Zheng MinHua
Publication year - 2009
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200900028
Subject(s) - colorectal cancer , biology , western blot , immunohistochemistry , metastasis , cancer , proteomics , cancer research , protein subunit , lymph node metastasis , oncology , bioinformatics , medicine , immunology , gene , genetics
Lymph node metastasis (LNM) is an important indicator for systematic therapy, which could increase the survival of colorectal cancer (CRC) patients. However, effective clinical evaluation for LNM is still absent to date. In this study, protein expression profiles of CRC tissues were compared between patients with and without LNM. Based on average expression level, 12 proteins were found to be differentially expressed in the CRC tissues with LNM, whose discrimination reliability was confirmed by PCA. With stepwise linear discriminant analysis, T‐complex protein 1 ζ subunit and peptidyl‐prolyl cis‐trans isomerase B (PPIB) were identified as two main contributors for separating CRC tissues with positive LNM from those negative ones in both original‐grouped and cross‐validated‐grouped cases, which was also supported in subsequent linear support vector machine analysis. In addition, the expression alterations of the two proteins were verified by Western blot and immunohistochemistry. Functional studies also confirmed the role of PPIB in migration and invasion of cancer cells. Taken together, the down‐regulated T‐complex protein 1 ζ subunit and up‐regulated PPIB were identified as two promising indicators for the clinical evaluation of LNM in CRC patients.